No Data
Spyre Therapeutics to Participate in Upcoming Investor Conference
Spyre Therapeutics Files for $500M Mixed Securities Shelf
Express News | Spartan Resources Ltd Files for Mixed Shelf of up to $500 Mln - SEC Filing
Express News | Spyre Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $45
Wedbush Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $45
Wedbush analyst David Nierengarten initiates coverage on $Spyre Therapeutics(SYRE.US)$ with a buy rating, and sets the target price at $45.According to TipRanks data, the analyst has a success rate
Buy Recommendation for Spyre Therapeutics Based on Promising IBD Pipeline and Strong Financial Position